The Russian Ministry of Health has registered a new vaccine against covid-19, CoviVac, the third developed in the country, announced today the Prime Minister of Russia, Mikhail Mishustin.
“I want to start with very good news. We found today that our third vaccine, the CoviVac, produced by the Chumakov Center, was registered”, Said the head of the Russian Government, at a meeting on the progress of the vaccination process in the country.
According to the Russian Prime Minister, Mikhail Mishustin, the first 120,000 doses of the new vaccine will enter circulation in mid-March, adding that the Russian pharmaceutical industry has been permanently increasing the production of vaccines against covid-19.
“We have already produced more than 10 million doses of the Sputnik V vaccine and about 80 thousand doses of EpiVacCorona and, soon, we will advance with the third production line of CoviVac ”, said the Russian Prime Minister, quoted by the TASS agency. We are now the only country in the world with three different vaccines against covid-19 ″, he stressed.
For her part, Deputy Prime Minister Tatiana Golíkova said that Russia intends to produce 88 million doses of vaccines during the first half this year, with 83 million from Sputnik V.
Regarding the vaccination process in the country, the deputy prime minister said that 45% of people over 60 were vaccinated, a percentage that he considered “insufficient”, having called on the regional authorities to intensify efforts.
Sputnik V, the first vaccine produced in Russia, revealed in a recent study to be 91.6% effective, which puts it among the best performing vaccines, such as that of Pfizer / BioNTech, which announces an efficiency of around 95%, using, however, a different technology (messenger RNA).
This means that an extra vaccine can be added to the fight against covid-19 ″, consider two British experts, Ian Jones and Polly Roy, in a comment attached to the study, published earlier this month in the scientific journal The Lancet.
There are now more than 50 countries that want the vaccine, but the high demand is starting to cause distribution problems.